Suppression of Metastatic Melanoma Growth in Lung by Modulated Electro-Hyperthermia Monitored by a Minimally Invasive Heat Stress Testing Approach in Mice.

B16F10 melanoma DNA double-strand breaks cell cycle arrest immune cell mobilization modulated electro-hyperthermia pulmonary metastases

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
21 Dec 2020
Historique:
received: 03 11 2020
revised: 05 12 2020
accepted: 17 12 2020
entrez: 29 12 2020
pubmed: 30 12 2020
medline: 30 12 2020
Statut: epublish

Résumé

Modulated electro-hyperthermia (mEHT) is a novel complementary therapy in oncology which is based on the higher conductivity and permittivity of cancerous tissues due to their enhanced glycolytic activity and ionic content compared to healthy normal tissues. We aimed to evaluate the potential of mEHT, inducing local hyperthermia, in the treatment of pulmonary metastatic melanoma. Our primary objective was the optimization of mEHT for targeted lung treatment as well as to identify the mechanism of its potential anti-tumor effect in the B16F10 mouse melanoma pulmonary metastases model while investigating the potential treatment-related side effects of mEHT on normal lung tissue. Repeated treatment of tumor-bearing lungs with mEHT induced significant anti-tumor effects as demonstrated by the lower number of tumor nodules and the downregulation of Ki67 expression in treated tumor cells. mEHT treatment provoked significant DNA double-strand breaks indicated by the increased expression of phosphorylated H2AX protein in treated tumors, although treatment-induced elevation of cleaved/activated caspase-3 expression was insignificant, suggesting the minimal role of apoptosis in this process. The mEHT-related significant increase in p21

Identifiants

pubmed: 33371498
pii: cancers12123872
doi: 10.3390/cancers12123872
pmc: PMC7767533
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Hungarian National Research, Development and Innovation Office
ID : NVKP_16-1-2016-0042
Organisme : Hungarian National Research, Development and Innovation Office
ID : KNN-121510
Organisme : Hungarian National Research, Development and Innovation Office
ID : K-125174
Organisme : Ministry of Innovation and Technology`s BIOImaging Excellence
ID : TKP2019
Organisme : Higher Education Institutional Excellence Programme of the Ministry of Human Capacities in Hungary
ID : EFOP-3.6.3-VEKOP-16-2017-00009
Organisme : Horizon 2020 research and innovation program under grant agreement
ID : No. 739593

Références

J Exp Clin Cancer Res. 2018 Nov 1;37(1):266
pubmed: 30382874
DNA Repair (Amst). 2016 Jun;42:63-71
pubmed: 27156098
BMJ Open. 2017 Nov 3;7(11):e017387
pubmed: 29102988
Melanoma Res. 2013 Aug;23(4):307-11
pubmed: 23787816
Int J Hyperthermia. 2018 May;34(3):276-283
pubmed: 28659004
Proc Natl Acad Sci U S A. 1984 Apr;81(7):2088-91
pubmed: 6585788
Integr Cancer Ther. 2018 Dec;17(4):1297-1303
pubmed: 30193538
Scand J Clin Lab Invest. 2015 Oct;75(6):482-6
pubmed: 26067609
Antioxid Redox Signal. 2014 Aug 10;21(5):723-9
pubmed: 24512276
J Nucl Med. 2017 Nov;58(11):1770-1775
pubmed: 28473598
Nucl Med Mol Imaging. 2017 Sep;51(3):233-239
pubmed: 28878849
Mol Cell Biol. 2009 May;29(10):2828-40
pubmed: 19273588
Eur Respir J. 2008 Feb;31(2):252-60
pubmed: 18057061
Cell Cycle. 2003 Sep-Oct;2(5):426-7
pubmed: 12963833
Int J Hyperthermia. 2015;31(7):784-92
pubmed: 26367194
Med Eng Phys. 2003 Mar;25(2):79-90
pubmed: 12538062
Front Immunol. 2016 Feb 16;7:52
pubmed: 26909082
Electromagn Biol Med. 2009;28(2):148-65
pubmed: 19811397
Mol Cell Biol. 2017 Aug 11;37(17):
pubmed: 28630280
Phys Med Biol. 2007 Aug 7;52(15):4707-19
pubmed: 17634659
Immunotargets Ther. 2018 Jun 07;7:35-49
pubmed: 29922629
Int J Mol Sci. 2019 Aug 17;20(16):
pubmed: 31426515
Cancers (Basel). 2020 Sep 10;12(9):
pubmed: 32927720
Eur J Nucl Med Mol Imaging. 2019 Jul;46(7):1485-1494
pubmed: 30949816
J Invest Surg. 1993 Jan-Feb;6(1):25-32
pubmed: 8452822
Respirology. 2009 Jan;14(1):27-38
pubmed: 19144046
Cell Stress Chaperones. 2015 Jan;20(1):37-46
pubmed: 24973890
J Oncol. 2012;2012:647684
pubmed: 22792102
Curr Protoc Immunol. 2001 May;Chapter 20:Unit 20.1
pubmed: 18432774
DNA Repair (Amst). 2004 Aug-Sep;3(8-9):959-67
pubmed: 15279782
Cancers (Basel). 2010 Dec 30;3(1):126-63
pubmed: 24212610
J Cancer. 2018 Jan 1;9(1):41-53
pubmed: 29290768
Cancer Med. 2019 Aug;8(9):4292-4303
pubmed: 31183995
Oncotarget. 2016 Dec 20;7(51):84082-84092
pubmed: 27556507
Strahlenther Onkol. 2014 Sep;190(9):815-22
pubmed: 24562547
FASEB J. 2013 Jun;27(6):2207-19
pubmed: 23413361

Auteurs

Mbuotidem Jeremiah Thomas (MJ)

Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.

Enikő Major (E)

Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.

Anett Benedek (A)

Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.

Ildikó Horváth (I)

Department of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.

Domokos Máthé (D)

Department of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.
Hungarian Centre of Excellence for Molecular Medicine (HCEMM), In Vivo Imaging Advanced Core Facility, 1094 Budapest, Hungary.

Ralf Bergmann (R)

Department of Biophysics and Radiation Biology, Semmelweis University, 1094 Budapest, Hungary.
Helmholtz-Zentrum Dresden Rossendorf, Institute of Radiopharmaceutical Cancer Research, 01328 Dresden, Germany.

Attila Marcell Szász (AM)

Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.

Tibor Krenács (T)

1st Department of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, Hungary.

Zoltán Benyó (Z)

Institute of Translational Medicine, Semmelweis University, 1094 Budapest, Hungary.

Classifications MeSH